Why bluebird bio Inc and Juno Therapeutics Inc Shot Higher Today – Madison.com
Madison.com |
Why bluebird bio Inc and Juno Therapeutics Inc Shot Higher Today
Madison.com Kite, Juno, and Bluebird are all developing chimeric antigen receptor (CAR) and the related engineered T–cell receptor (TCR) technologies, which make genetic changes to patient's immune T cells, training them to attack cancer cells. Kite is … |
